Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans

Langenbeck's Archives of Surgery

Volumn 383, Issue 2, 1998, Pages 160-163

  Altenvoerde, G ^a   Lerch, H ^a   Kuwert, T ^a   Matheja, P ^a   Schafers M ^a   Schober, O ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Elevated thyroglobulin; FDG PET; Thyroid carcinoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; THYROGLOBULIN; THYROTROPIN; THYROXINE;

ADULT; AGED; ARTICLE; BONE METASTASIS; CANCER RECURRENCE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MEDIASTINUM METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE THERAPY; THYROGLOBULIN BLOOD LEVEL; THYROID CARCINOMA; THYROID SCINTISCANNING;

EID: 0031712448     PISSN: 14352443     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004230050109     Document Type: Article

References (25)

1. Ashcraft MW, van Herle AJ (1981) The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer. Am J Med 71: 806-814
2. Black EG, Cassoni A, Gimlette TMD, Harmer CL, Maisey MN, Oates GD, Hoffenberg R (1981) Serum thyroglobulin in thyroid cancer. Lancet: 443-445
3. DeGroot LJ, Kaplan EL, McCormick M, Straus FH (1990) Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 71: 414-424
4. DeGroot LJ, Kaplan EL, Shukla MS, Salti MS, Straus FH (1995) Morbidity and mortality in follicular thyroid cancer. J Clin Endocrinol Metab 80: 2946-2953
5. Farahati J, Reiners C, Stuschke M, Muller SP, Stuben G, Sauerwein W, Sack H (1996) Differentiated thyroid cancer: impact of external radiotherapy in patients with perithyroidal tumor infiltration (Stage pT4). Cancer 77: 172-180
6. Feine U, Lietzenmayer R, Hanke JP, Wöhrle H, Müller-Schauenburg W (1995) F-18-FDG-Ganzkörper-PET beim differenzierten Schilddrüsenkarzinom. Nuklearmedizin 34. 127-134
7. Feine U, Lietzenmayer R, Hanke JP, Held J, Wöhrle H, MüllerSchauenburg W (1996) Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 37: 1468-1472
8. Flower MA, Schlesinger T, Hinton PJ, Adam I, Masoomi AM, Elbelli MA, Ott RJ, McCready VR, Harmer CL (1989) Radiation dose assessment in radioiodine therapy. 2: Practical implementation using quantitative scanning and PET. with initial results on thyroid carcinoma. Radiother Onkol 15: 345-357
9. Franceschi M, Kusic Z, Franceschi D, Lukinac L, Roncevic S (1996) Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 37: 446-451
10. Friedrich L, Messa C, Landoni C, Lucignani G, Moncayo R, Kendler D, Riccabona G, Fazio F (1997) Whole-body-scintigraphy with 99m-Tc-MIBI, F-18-FDG and I-131 in patients with metastatic thyroid carcinoma. Nucl Med Commun 18: 3-9
11. Goretzki PE, Simon D, Frilling A, Witte J, Reiners C, Grussendorf M, Horster FA, Röhrer HD (1993) Surgical reintervention for differentiated thyroid cancer. Br J Surg 80: 1009-1012
12. Grünwald F, Schomburg A, Bender H, Klemm E, Menzel C, Bultan T, Plamedo H, Ruhlmann J, Kozak B, Biersack HJ (1996) Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 23: 312-319
13. Lerch H, Schober O, Kuwert T, Saur HB (1997) Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol 15: 2067-2075
14. Lo Gerfo P, Stillman T, Colacchio D, Feind C (1977) Serum thyroglobulin and recurrent thyroid cancer. Lancet: 881-882
15. Mazzaferri EL (1995) Treating high thyroglobulin with radioiodine: a magic bullet or a shot in the dark? J Clin Endocrinol Metab 80: 1485-1497
16. Mazzaferri EL, Jhiang SM (1994) Long term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97: 418-428
17. Pacini F, Lippi F, Formica N, Elisei R, Anelli S, Ceccarelli C, Pinchera A (1987) Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels. J Nucl Med 28: 1888-1891
18. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J (1995) Iodine131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. J Clin Endocriol Metab 80: 1488-1492
19. Scheumann GFW, Grimm O, Wegener G, et al (1994) Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 18: 559-565
20. Schober O, Saur HB, Sciuk J, Ahrens S (1994) Radioiodine therapy of malignant thyroid disease. Exp Clin Endocrinol 102: 55-66
21. Scott GC, Meier DA, Dickinson CZ (1995) Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG. technetium-99m-pertechnetate and iodine-131-sodium iodide. J Nucl Med 36: 1843-1845
22. Szanto J, Vincze B, Sinkovics I, Karika Z, Daubner K, Peter I, Kazatsay I, Eckhardt S (1989) Postoperative thyroglobulin level determination to follow up patients with highly differentiated thyroid cancer. Oncol 46: 99-104
23. Tatsch W, Weber W, Roßmüller B, Langhammer HR, Schwaiger M, Hahn K (1997) FDG-PET in patients with thyroid carcinoma presenting with elevated thyroglobulin but negative iodine- and SESTAMIBI-scans. J Nucl Med 38:155P
24. Van Herle AJ, Uller RP (1975) Elevated serum thyroglobulin: a marker of metastases in differentiated thyroid carcinomas. J Clin Invest 56: 272-277
25. Van Herle AJ, Van Herle IS, Greipel MA (1985) An international cooperative study evaluating serum thyroglobulin standards. J Clin Endocrinol Metab 60: 338-343